Qurient Co. Ltd Asset Resilience Ratio

Latest as of June 2026: 71.23%

Qurient Co. Ltd asset resilience ratio. Qurient Co. Ltd (115180) has an Asset Resilience Ratio of 71.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 115180 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩32.45 Billion
≈ $21.99 Million USD Cash + Short-term Investments

Total Assets

₩45.56 Billion
≈ $30.88 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Qurient Co. Ltd (2016–2025)

Asset resilience ratio of Qurient Co. Ltd from 2016 to 2025. This chart shows how Qurient Co. Ltd's Asset Resilience Ratio has changed over time. Read 115180 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Qurient Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Qurient Co. Ltd asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩32.45 Billion 71.23%
Total Liquid Assets ₩32.45 Billion 71.23%

Asset Resilience Insights

  • Very High Liquidity: Qurient Co. Ltd maintains exceptional liquid asset reserves at 71.23% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Qurient Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Qurient Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Qurient Co. Ltd Asset Resilience Ratio by Year (2016–2025)

Qurient Co. Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Qurient Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 46.80% ₩29.02 Billion
≈ $19.66 Million
₩61.99 Billion
≈ $42.01 Million
-23.82pp
2024-12-31 70.62% ₩46.31 Billion
≈ $31.38 Million
₩65.57 Billion
≈ $44.44 Million
-7.24pp
2023-12-31 77.86% ₩40.88 Billion
≈ $27.70 Million
₩52.50 Billion
≈ $35.58 Million
+9.74pp
2022-12-31 68.12% ₩26.17 Billion
≈ $17.73 Million
₩38.41 Billion
≈ $26.03 Million
+10.09pp
2021-12-31 58.03% ₩33.44 Billion
≈ $22.66 Million
₩57.62 Billion
≈ $39.05 Million
-22.76pp
2018-12-31 80.80% ₩34.90 Billion
≈ $23.65 Million
₩43.20 Billion
≈ $29.27 Million
+17.69pp
2017-12-31 63.10% ₩9.89 Billion
≈ $6.70 Million
₩15.68 Billion
≈ $10.62 Million
+55.48pp
2016-12-31 7.62% ₩2.00 Billion
≈ $1.36 Million
₩26.24 Billion
≈ $17.78 Million
--
pp = percentage points

About Qurient Co. Ltd

KQ:115180 Korea Biotechnology
Market Cap
$410.10 Million
₩605.15 Billion KRW
Market Cap Rank
#12969 Global
#372 in Korea
Share Price
₩16240.00
Change (1 day)
+2.53%
52-Week Range
₩14850.00 - ₩50900.00
All Time High
₩50900.00
About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more